Want to see NXPL full AI Analyst Report?
Top Page
NextPlat
(NASDAQ:NXPL)
Select Model
Select Model
Rating:49Neutral
Price Target:
$9.00
▼(-3.43% Downside)
Action:Reiterated
Date:10/06/26
NXPL’s score is held back primarily by weak financial performance (persistent losses, negative cash flow, and recent revenue declines), despite some balance-sheet support from low leverage. Technical signals are moderately constructive with price above key longer-term averages and a positive MACD. Valuation remains challenged due to losses (negative P/E) and no dividend yield support, while the recent profitable pharmacy acquisition is a modest positive catalyst.
Positive Factors
Low leverage
Low leverage reduces refinancing and solvency pressure, giving NextPlat more flexibility to manage uneven operating results and pursue selected growth initiatives. This balance-sheet support can help the company absorb volatility without the immediate burden of substantial interest obligations.
Negative Factors
Recent revenue contraction
The reversal from earlier scale-up to declining revenue indicates that growth has not yet become consistent. Sustained contraction could reduce operating leverage, weaken purchasing and marketing efficiency, and make it harder for NextPlat to reach profitability.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage
Low leverage reduces refinancing and solvency pressure, giving NextPlat more flexibility to manage uneven operating results and pursue selected growth initiatives. This balance-sheet support can help the company absorb volatility without the immediate burden of substantial interest obligations.
Read all positive factors
NextPlat (NXPL) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$24.42M
Dividend YieldN/A
Average Volume (3M)17.38K
Price to Earnings (P/E)―
Beta (1Y)1.16
Revenue Growth-17.82%
EPS Growth19.42%
CountryUS
Employees126
SectorTechnology
Sector Strength88
IndustrySoftware - Application
Share Statistics
EPS (TTM)-3.81
Shares Outstanding2,713,222
10 Day Avg. Volume6,018
30 Day Avg. Volume17,376
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)0.80
Price to Sales (P/S)0.26
P/FCF Ratio-2.24
Enterprise Value/Market Cap0.33
Enterprise Value/Revenue0.17
Enterprise Value/Gross Profit0.63
Enterprise Value/Ebitda-1.02
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.55
Revenue Forecast (FY)$48.85M
NextPlat Business Overview & Revenue Model
Company Description
NextPlat Corp, along with its subsidiaries, specializes in providing advanced mobile satellite services (MSS). These offerings encompass satellite-enabled voice and data communication, comprehensive personnel and asset tracking, machine-to-machine...
How the Company Makes Money
NextPlat primarily makes money by selling products through e-commerce channels and earning the spread between its product revenue and the cost to source, fulfill, and market those products (i.e., retail/e-commerce gross margin). A second core reve...
NextPlat Earnings Call Summary
Earnings Call Date:May 14, 2026
(Q1-2026)
| % Change Since: |
Next Earnings Date:Nov 16, 2026
Earnings Call Sentiment Positive
The call communicates a clear and measurable operational turnaround: substantial margin expansion, sharply reduced operating losses, the healthcare segment returning to profitability, growth in higher-margin pharmacy contract revenue, and stabilized e-commerce performance. These positive developments are counterbalanced by meaningful declines in top-line revenue (both YoY and sequential), an ongoing legal matter, prior Nasdaq compliance actions (reverse split) and the potential dilution implied by an ATM facility. On balance, the improvements in profitability, margins, and segment-level performance are material and portrayed as sustainable catalysts for future growth, outweighing the remaining revenue and corporate governance headwinds.Positive Updates
Significant Gross Margin Expansion
Consolidated gross margin expanded to approximately 35% in Q1 2026, up from ~21% in Q1 2025 (+14 percentage points YoY) and up from ~18% in Q4 2025 (+17 percentage points sequential). Consolidated gross profit rose to ~$3.4M (from ~$2.9M YoY, +17.2%).
Negative Updates
Total Revenue Decline YoY and Sequential
Total net revenues were approximately $10M in Q1 2026, down from ~$14M in the prior year period (-~28.6% YoY) and down from ~$13M in Q4 2025 (-~23.1% sequential), reflecting the effects of prior restructuring and shifting revenue mix.
Read all updates
Q1-2026 Updates
Positive
Negative
Significant Gross Margin Expansion
Consolidated gross margin expanded to approximately 35% in Q1 2026, up from ~21% in Q1 2025 (+14 percentage points YoY) and up from ~18% in Q4 2025 (+17 percentage points sequential). Consolidated gross profit rose to ~$3.4M (from ~$2.9M YoY, +17.2%).
Read all positive updates
Company Guidance
Guidance: management expects operational profitability in the latter half of 2026 with meaningful reductions in operating losses in H2 as new higher‑margin 340B and medication‑fulfillment customers ramp (the company signed five new 340B agreements this quarter that require ~90 days to onboard and are expected to contribute in Q3) and a new e‑commerce healthcare site is slated to go live before the end of Q2. Key metrics supporting that guidance: Q1 net revenues ≈ $10.0M (healthcare ≈ $7.0M, e‑commerce ≈ $3.2M; healthcare ≈ 68% of revenue), pharmacy contract revenue ≈ $1.9M (vs $1.6M in Q4’25 and $1.4M year‑ago), average 7,500 prescriptions filled/month to Florida contract facilities, consolidated gross profit ≈ $3.4M and gross margin ≈ 35% (vs ~21% in Q1’25 and ~18% in Q4’25), pharmacy gross margin ≈ 39% (vs ~20% prior year), total operating expenses ≈ $4.5M (salaries ≈ $2.4M), operating loss ≈ $1.1M (improved from ~$2.1M year‑ago and ~$2.8M Q4’25), cash ≈ $11M and working capital ≈ $14M; management also cited nationwide expansion to all 50 states, record IoT/e‑commerce demand across 130+ countries, and an ATM facility in place for optional capital although there are no current plans to access it.NextPlat Financial Statement Overview
Summary
Income Statement
26
Negative
Balance Sheet
58
Neutral
Cash Flow
22
Negative
| Breakdown | TTM | Mar 2026 | Dec 2024 | Mar 2024 | Mar 2023 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 48.29M | 54.32M | 65.48M | 37.76M | 11.71M | 7.74M |
| Gross Profit | 12.67M | 10.91M | 16.23M | 11.31M | 2.49M | 1.86M |
| EBITDA | -7.86M | -9.36M | -20.15M | -19.68M | -6.71M | -6.29M |
| Net Income | -9.84M | -11.71M | -14.03M | -3.78M | -9.16M | -8.11M |
Balance Sheet | ||||||
| Total Assets | 28.67M | 27.46M | 36.48M | 64.47M | 28.64M | 20.57M |
| Cash, Cash Equivalents and Short-Term Investments | 11.94M | 13.71M | 19.96M | 26.31M | 18.89M | 17.27M |
| Total Debt | 1.58M | 1.49M | 2.26M | 3.01M | 1.07M | 365.22K |
| Total Liabilities | 12.19M | 10.04M | 9.68M | 16.38M | 2.87M | 3.03M |
| Stockholders Equity | 16.39M | 17.31M | 26.68M | 32.18M | 25.78M | 17.53M |
Cash Flow | ||||||
| Free Cash Flow | -4.57M | -6.20M | -5.65M | -4.24M | -4.32M | -4.32M |
| Operating Cash Flow | -4.53M | -6.13M | -5.46M | -3.60M | -3.60M | -4.09M |
| Investing Cash Flow | 65.00K | 163.00K | -953.00K | 5.20M | -7.72M | -229.31K |
| Financing Cash Flow | -252.00K | -225.00K | 72.00K | 5.86M | 13.01M | 20.82M |
NextPlat Technical Analysis
Positive
9.32
Price Trends
8.64
Positive
7.55
Positive
6.65
Positive
Market Momentum
0.08
Positive
51.66
Neutral
46.13
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NXPL, the sentiment is Positive. The current price of 9.32 is above the 20-day moving average (MA) of 9.05, above the 50-day MA of 8.64, and above the 200-day MA of 6.65, indicating a neutral trend. The MACD of 0.08 indicates Positive momentum. The RSI at 51.66 is Neutral, neither overbought nor oversold. The STOCH value of 46.13 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for NXPL.
NextPlat Risk Analysis
NextPlat disclosed 28 risk factors in its most recent earnings report. NextPlat reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
NextPlat Peers Comparison
UnderperformOutperform
Sector (61)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
61 Neutral | $37.18B | 12.37 | -10.20% | 1.83% | 8.50% | -7.62% | |
51 Neutral | $15.59M | -2.21 | -21.12% | ― | ― | ― | |
49 Neutral | $24.42M | -2.39 | -54.98% | ― | -17.82% | 19.42% | |
48 Neutral | $4.67M | -0.06 | -135.04% | ― | -20.40% | 32.15% | |
42 Neutral | $117.11M | -1.59 | -63.41% | ― | 34.88% | 12.77% | |
39 Underperform | $2.17M | -0.03 | -228.97% | ― | 25.23% | -144.16% |
* Technology Sector Average
NXPL
NextPlat
9.12
0.88
10.62%
IPM
Intelligent Protection Management
1.75
-0.26
-13.18%
CXAI
CXApp
1.87
-39.33
-95.46%
RYDE
Ryde Group Limited Class A
0.70
0.14
23.89%
WCT
Wellchange Holdings Company Limited
0.48
-83.49
-99.43%
NTCL
NetClass Technology Inc Class A
0.86
-62.64
-98.65%
NextPlat Corporate Events
Business Operations and StrategyFinancial DisclosuresM&A Transactions
NextPlat Expands Rural Pharmacy Footprint in Northwest Florida
Positive
Oct 6, 2026
On October 6, 2026, NextPlat Corp completed the acquisition of a profitable independent pharmacy in a rural community near Pensacola, Florida, paying $1.49 million in cash for the business and its inventory. The pharmacy, which generated about $5....
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.